A Phase 4 interventional study of arginine/lysine in Gastroenteropancreatic Neuroendocrine Tumors, sponsored by Advanced Accelerator Applications. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Advanced Accelerator Applications (part of Novartis) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post start of infusion compared to baseline.
The study schedule for each patient consisted of a screening period followed by an infusion day with an optional overnight in-clinic stay, and a follow up call 48h post infusion.
Screening Phase:
At screening, patient eligibility was determined according to inclusion and exclusion criteria, with evaluation of patient's vital signs, ECG and laboratory parameters. The duration of screening could be as short as one day but could not exceed 7 days. Patients who showed potassium level > 6.0 mmol/L (> 5.5 mmol/L for Poland only) at screening could have their potassium level corrected and could be re-screened afterwards.
Treatment Phase:
Eligible patients were admitted to the in-clinic unit and dosed with arginine/lysine solution for infusion of 1,000 mL, which was administered intravenously over a period of 4 hours. Before the infusion (at 0 h time point), a set of baseline tests were performed. During and after the infusion, patient condition was monitored for evaluation of any adverse events. Only patients with a potassium level of ≤ 6 mmol/L at screening (> 5.5 mmol/L for Poland only) were allowed to be dosed. Potassium testing on the infusion day was performed at 0h (before the infusion), and at 2h, 4h, 6h, 8h, 12h, and 24h after the start of infusion. Vital signs and ECGs were taken as specified in the assessment schedule. All patients were monitored closely for signs and symptoms of hyperkalemia, e.g. dyspnoea, weakness, numbness, chest pain and cardiac manifestations (conduction abnormalities and cardiac arrhythmias). Other common adverse reactions during arginine/lysine solution administration are nausea and vomiting. Before the start of arginine/lysine solution infusion, an intravenous bolus of an anti-emetic was given. The choice of anti-emetic drugs was at the discretion of the physician.
Follow-up Phase:
All patients were called for a safety follow-up in 48 hours after dosing. Patients were not scheduled to receive repeat dosing with arginine/lysine solution as concomitant medication with Lutathera® within 7 days of the arginine/lysine solution infusion in the study.
73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.
This study's enrollment of 42 is below the median of 53 across 49 interventional studies indexed under Gastro-enteropancreatic neuroendocrine tumor.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →Advanced Accelerator Applications is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
First submitted after Advanced Accelerator Applications became part of Novartis.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria (Poland Only):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of arginine/lysine solution administered intravenously over a 4-hour period
Drug: arginine/lysine
Mean Change From Baseline in Serum Potassium Levels Over 24 Hours
Serum potassium levels at each collection time point will be measured at local laboratories of study sites using validated methods. The potassium concentration results will be summarized descriptively and will include mean change, maximum change, time to the maximum change, and the overall dynamics of the potassium concentration curve during and after the arginine/lysine infusion.
Time frame: Day 0/Infusion Day (Hour 0, Hour 2, Hour 4, Hour 6, Hour 8, Hour 12, Hour 24)
Percentage of Participants With Treatment Adverse Events (AEs) & Serious Adverse Events (SAEs)
Safety measured by the percentage of participants with treatment emergent adverse events (starting from the signing of the ICF until the end of the follow-up call (48 hours after infusion).
Time frame: Day 0/Infusion Day up to 48 hours post infusion
Number of Participants With Notable Changes in Vital Signs
Safety measured by the notable post-baseline changes in vital signs: (systolic blood pressure, diastolic blood pressure, pulse rate \& weight) compared to baseline.
Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Number of Participants With Notable Changes in Electrocardiogram (ECG)
Safety measured by the notable post-baseline changes in ECG values compared to baseline PR, QRS, QT, QTcF, and RR intervals were obtained from 12-lead ECGs for each subject during the study
Time frame: Day 0/Infusion Day (0, 4, 8 and 24 hours)
Number of Participants With Notable Changes in Hematology Parameters
Safety measured by the notable post-baseline changes in Hematology parameters compared to baseline as represented by Shift tables based on common toxicity criteria (CTC) grades. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.
Time frame: Day 0/Infusion Day (0 and 24 hours)
Number of Participants With Notable Changes in Chemistry Parameters
Safety measured by the notable post-baseline changes in Chemistry parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline. Key shifts were in the following parameters: creatinine, lactate dehydrogenase and creatinine clearance.
Time frame: Day 0/Infusion Day (0 and 24 hours)
Number of Participants With Notable Changes in Electrolyte Parameters
Safety measured by the notable post-baseline changes in Electrolyte parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.
Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Mean Change From Baseline in Blood Gas Parameter, pH, Over 24 Hours
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: pH.
Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Mean Change From Baseline in Blood Gas Parameter, Lactic Acid, Over 24 Hours
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Lactic Acid
Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Mean Change From Baseline in Blood Gas Parameter, Partial Pressure Carbon Dioxide, Over 24 Hours
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Partial Pressure Carbon Dioxide.
Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
A total of 42 participants were enrolled in 7 centers in 4 countries.
| Milestone | GEP-NET |
|---|---|
| Started | 42 |
| Treated | 41 |
| Not treated | 1 |
| Post-treatment follow-up phase (48 hrs post-infusion) | 40 |
| Completed | 41 |
| Not completed | 1 |
| Withdrew: Subject decision | 1 |
Serum potassium levels at each collection time point will be measured at local laboratories of study sites using validated methods. The potassium concentration results will be summarized descriptively and will include mean change, maximum change, time to the maximum change, and the overall dynamics of the potassium concentration curve during and after the arginine/lysine infusion.
| mmol/L | GEP-NET |
|---|---|
| Pre-dose (hour 0) | 4.3 ± 0.397 |
| Change from Baseline (BL) to Hour 2 | 0.25 ± 0.452 |
| Change from Baseline (BL) to Hour 4 | 0.60 ± 0.666 |
| Change from Baseline (BL) to Hour 6 | 0.49 ± 0.602 |
| Change from Baseline (BL) to Hour 8 | 0.38 ± 0.487 |
| Change from Baseline (BL) to Hour 12 | 0.24 ± 0.557 |
| Change from Baseline (BL) to Hour 24 | 0.07 ± 0.396 |
Safety measured by the percentage of participants with treatment emergent adverse events (starting from the signing of the ICF until the end of the follow-up call (48 hours after infusion).
| Participants | GEP-NET |
|---|---|
| Adverse Event (AEs) | 11 |
| Treatment-related AEs | 6 |
| Serious Adverse Events (SAEs) | 0 |
| Fatal SAEs | 0 |
| AEs leading to discontinuation | 0 |
| AEs leading to Interrruption | 0 |
| AEs requiring additional therapy | 5 |
| Treatment related AEs req. additional therapy | 3 |
Safety measured by the notable post-baseline changes in vital signs: (systolic blood pressure, diastolic blood pressure, pulse rate \& weight) compared to baseline.
| Participants | GEP-NET |
|---|---|
| Systolic blood pressure (mmHg): ≥180 with increase from baseline of ≥20 | 0 |
| Systolic blood pressure (mmHg): ≤ 90 with decrease from baseline of ≥20 | 0 |
| Diastolic blood pressure (mmHg): ≥105 with increase from baseline of ≥15 | 0 |
| Diastolic blood pressure (mmHg): ≤ 50 with decrease from baseline of ≥15 | 0 |
| Pulse rate (bpm): ≥100 with increase from baseline of >25% | 0 |
| Pulse rate (bpm): ≤ 50 with decrease from baseline of > 25% | 0 |
| Weight (kg): increase ≥10% from Baseline | 0 |
| Weight (kg): decrease > 10% from Baseline | 0 |
Safety measured by the notable post-baseline changes in ECG values compared to baseline PR, QRS, QT, QTcF, and RR intervals were obtained from 12-lead ECGs for each subject during the study
| Participants | GEP-NET |
|---|---|
| QTcF (ms): Increase >30 to ≤ 60 ms | 7 |
| QTcF (ms): Increase >60 ms | 0 |
| QTcF (ms): New >450 to ≤ 480 ms | 7 |
| QTcF (ms): New >480 to ≤ 500 ms | 0 |
| QTcF (ms); New >500 ms | 0 |
| QT (ms): Increase >30 to ≤ 60 ms | 9 |
| QT (ms): Increase >60 ms | 2 |
| QT (ms): New >450 to ≤ 480 ms | 6 |
| QT (ms): New >480 to ≤ 500 ms | 1 |
| QT (ms): New >500 ms | 0 |
| PR (ms): Increase >25% and PR >200 ms | 1 |
| PR (ms): New PR >200 ms | 6 |
| QRS (ms): Increase >25% and QRS >120 ms | 2 |
| QRS (ms): New QRS >120 ms | 2 |
| HR (bpm): Increase >25% and HR >100 bpm | 0 |
| HR (bpm): Decrease >25% and HR <50 bpm | 0 |
Safety measured by the notable post-baseline changes in Hematology parameters compared to baseline as represented by Shift tables based on common toxicity criteria (CTC) grades. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.
| Participants | GEP-NET |
|---|---|
| Number of Participants With Notable Changes in Hematology Parameters | 0 |
Safety measured by the notable post-baseline changes in Chemistry parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline. Key shifts were in the following parameters: creatinine, lactate dehydrogenase and creatinine clearance.
| Participants | GEP-NET |
|---|---|
| Creatinine (increase) | 4 |
| Lactate dehydrogenase (increase) | 3 |
| Creatinine clearance (decrease) | 4 |
Safety measured by the notable post-baseline changes in Electrolyte parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.
| Participants | GEP-NET |
|---|---|
| For Potassium (increase) | 7 |
| For sodium (decrease) | 12 |
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: pH.
| unitless | GEP-NET |
|---|---|
| Day 0/Infusion Day (Pre-dose) (hour 0) | 7.35 ± 0.046 |
| Change from Baseline (BL) to Hour 2 | -0.03 ± 0.046 |
| Change from Baseline (BL) to Hour 4 | -0.06 ± 0.055 |
| Change from Baseline (BL) to Hour 6 | -0.05 ± 0.051 |
| Change from Baseline (BL) to Hour 8 | -0.05 ± 0.056 |
| Change from Baseline (BL) to Hour 12 | -0.03 ± 0.054 |
| Change from Baseline (BL) to Hour 24 | -0.04 ± 0.051 |
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Lactic Acid
| mmol/L | GEP-NET |
|---|---|
| Day 0/Infusion Day (Pre-dose) (hour 0) | 1.40 ± 0.604 |
| Change from Baseline (BL) to Hour 2 | -0.07 ± 0.671 |
| Change from Baseline (BL) to Hour 4 | -0.23 ± 0.523 |
| Change from Baseline (BL) to Hour 6 | -0.26 ± 0.546 |
| Change from Baseline (BL) to Hour 8 | -0.19 ± 0.465 |
| Change from Baseline (BL) to Hour 12 | -0.21 ± 0.657 |
| Change from Baseline (BL) to Hour 24 | -0.16 ± 0.650 |
Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Partial Pressure Carbon Dioxide.
| mmHg | GEP-NET |
|---|---|
| Day 0/Infusion Day (Pre-dose) (hour 0) | 50.53 ± 8.712 |
| Change from Baseline (BL) to Hour 2 | -1.08 ± 6.670 |
| Change from Baseline (BL) to Hour 4 | -2.44 ± 8.717 |
| Change from Baseline (BL) to Hour 6 | -4.90 ± 8.507 |
| Change from Baseline (BL) to Hour 8 | -4.87 ± 8.399 |
| Change from Baseline (BL) to Hour 12 | -5.71 ± 8.002 |
| Change from Baseline (BL) to Hour 24 | -2.54 ± 8.242 |
Collected over Adverse Events (AEs) were collected from the administration of the study treatment up to 48 hours in addition to the infusion time, an average of 52 hours total.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/41 (0%) | 0/41 (0%) | 11/41 (26.8%) |
| Event | All Participants |
|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 5/41 |
| NauseaGastrointestinal disorders | 2/41 |
| Abdominal painGastrointestinal disorders | 1/41 |
| ProctalgiaGastrointestinal disorders | 1/41 |
| VomitingGastrointestinal disorders | 1/41 |
| FatigueGeneral disorders | 1/41 |
| ContusionInjury, poisoning and procedural complications | 1/41 |
| DizzinessNervous system disorders | 1/41 |
| HeadacheNervous system disorders | 1/41 |
| Respiratory acidosisRespiratory, thoracic and mediastinal disorders | 1/41 |
Safety Set: The Safety Set (SAF) comprises all subjects who received any administration of the LysaKare infusion in the study.
| Age, Continuous(Years) | GEP-NET |
|---|---|
| Mean | 57.7 ± 9.46 |
| Sex: Female, Male(Participants) | GEP-NET |
|---|---|
| Female | 19 |
| Male | 22 |
| Race/Ethnicity, Customized(Participants) | GEP-NET |
|---|---|
| White | 38 |
| Black or African American | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jan 2021 to primary completion in Nov 2023, 33 months.
Results were first posted in Jan 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arginine · Lysine
Gastro-enteropancreatic neuroendocrine tumor →
Advanced Accelerator Applications →